Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 8 for:    azilsartan hypertension children

A Phase 3 Pharmacokinetic Study of TAK-536 (Azilsartan) in Pediatric Patients 6 to Less Than 16 Years With Hypertension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02451150
Recruitment Status : Completed
First Posted : May 21, 2015
Results First Posted : April 7, 2016
Last Update Posted : April 7, 2016
Sponsor:
Information provided by (Responsible Party):
Takeda

Brief Summary:
The purpose of this study is to evaluate the pharmacokinetics and safety of a single dose of TAK-536 (azilsartan) in pediatric patients aged 6 to less than 16 years with hypertension.

Condition or disease Intervention/treatment Phase
Pediatric Hypertension Drug: Azilsartan Phase 3

Detailed Description:

The drug being tested in this study is called azilsartan. Azilsartan was being tested to evaluate how it is processed by the body (pharmacokinetics). This study looked at lab results in pediatric participants who took azilsartan.

The study enrolled 6 patients. Participants were assigned to study medication dose by body weight as follows:

  • Body Weight <50 kg: azilsartan 5 mg
  • Body Weight ≥50 kg: azilsartan 10 mg

All participants took a single oral dose of azilsartan on Day 1 of the study.

This multi-center trial was conducted in Japan. The overall time to participate in this study was 17 days. Participants made multiple visits to the clinic, and were contacted by telephone on Day 6 and Day 15 after last dose of study drug for a follow-up assessment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Phase 3, Multicenter Study to Evaluate the Pharmacokinetics Following a Single Oral Dose of TAK-536 in Pediatric Patients 6 to Less Than 16 Years of Age With Hypertension
Study Start Date : August 2015
Actual Primary Completion Date : September 2015
Actual Study Completion Date : September 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Azilsartan 5 mg
Weight <50 kg: azilsartan 5 mg, tablets, orally, once, after breakfast on Day 1.
Drug: Azilsartan
Azilsartan tablets
Other Name: TAK-536

Experimental: Azilsartan 10 mg
Weight ≥50 kg: azilsartan 10 mg, tablets, orally, once, after breakfast on Day 1.
Drug: Azilsartan
Azilsartan tablets
Other Name: TAK-536




Primary Outcome Measures :
  1. AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to Time 24 Hours of TAK-536 (Azilsartan) [ Time Frame: Pre-dose and at multiple time points (up to 24 hours) post-dose ]
    AUC(0-24) is a measure of total plasma exposure to the drug from time 0 to 24 hours post-dose, calculated using the linear trapezoidal rule.

  2. Cmax: Maximum Observed Plasma Concentration of TAK-536 (Azilsartan) [ Time Frame: Pre-dose and at multiple time points (up to 24 hours) post-dose ]
    Cmax is the maximum observed plasma concentration (actual measurement value) of a drug after administration, obtained directly from the plasma concentration-time curve.

  3. AUC(0-inf): Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity of TAK-536 (Azilsartan) [ Time Frame: Pre-dose and at multiple time points (up to 24 hours) post-dose ]
    AUC(0-inf) is a measure of total plasma exposure to the drug from time zero extrapolated to infinity, calculated as AUC(0-inf)=AUC(0-tlqc)+lqc/λz

  4. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) of TAK-536 (Azilsartan) [ Time Frame: Pre-dose and at multiple time points (up to 24 hours) post-dose ]
    Tmax is the time to reach Cmax (actual measurement value), equal to time (hours) to Cmax.

  5. T1/2: Terminal Elimination Half-Life of TAK-536 (Azilsartan) [ Time Frame: Pre-dose and at multiple time points (up to 24 hours) post-dose ]
    T1/2 is the terminal elimination half-life (time required for half of the drug to be eliminated from the plasma), calculated as T1/2=ln(2)/λz.

  6. AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to Time 24 Hours of TAK-536 (Azilsartan) Metabolite M-I [ Time Frame: Pre-dose and at multiple time points (up to 24 hours) post-dose ]
    AUC(0-24) is a measure of total plasma exposure to the drug from time 0 to 24 hours post-dose, calculated using the linear trapezoidal rule.

  7. Cmax: Maximum Observed Plasma Concentration of TAK-536 (Azilsartan) Metabolite M-I [ Time Frame: Pre-dose and at multiple time points (up to 24 hours) post-dose ]
    Cmax is the maximum observed plasma concentration (actual measurement value) of a drug after administration, obtained directly from the plasma concentration-time curve.

  8. AUC(0-inf) Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity of TAK-536 (Azilsartan) Metabolite M-I [ Time Frame: Pre-dose and at multiple time points (up to 24 hours) post-dose ]
    AUC(0-inf) is a measure of total plasma exposure to the drug from time zero extrapolated to infinity, calculated as AUC(0-inf)=AUC(0-tlqc)+lqc/λz.

  9. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) of TAK-536 (Azilsartan) Metabolite M-I [ Time Frame: Pre-dose and at multiple time points (up to 24 hours) post-dose ]
    Tmax is the time to reach Cmax (actual measurement value), equal to time (hours) to Cmax.

  10. T1/2: Terminal Elimination Half-Life of TAK-536 (Azilsartan) Metabolite M-I [ Time Frame: Pre-dose and at multiple time points (up to 24 hours) post-dose ]
    T1/2 is the terminal elimination half-life (time required for half of the drug to be eliminated from the plasma), calculated as T1/2=ln(2)/λz.

  11. AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to Time 24 Hours of TAK-536 (Azilsartan) Metabolite M-II [ Time Frame: Pre-dose and at multiple time points (up to 24 hours) post-dose ]
    AUC(0-24) is a measure of total plasma exposure to the drug from time 0 to 24 hours post-dose, calculated using the linear trapezoidal rule.

  12. Cmax: Maximum Observed Plasma Concentration of TAK-536 (Azilsartan) Metabolite M-II [ Time Frame: Pre-dose and at multiple time points (up to 24 hours) post-dose ]
    Cmax is the maximum observed plasma concentration (actual measurement value) of a drug after administration, obtained directly from the plasma concentration-time curve.

  13. AUC(0-inf) Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity of TAK-536 (Azilsartan) Metabolite M-II [ Time Frame: Pre-dose and at multiple time points (up to 24 hours) post-dose ]
    AUC(0-inf) is a measure of total plasma exposure to the drug from time zero extrapolated to infinity, calculated as AUC(0-inf)=AUC(0-tlqc)+lqc/λz.

  14. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) of TAK-536 (Azilsartan) Metabolite M-II [ Time Frame: Pre-dose and at multiple time points (up to 24 hours) post-dose ]
    Tmax is the time to reach Cmax (actual measurement value), equal to time (hours) to Cmax.

  15. T1/2: Terminal Elimination Half-Life of TAK-536 (Azilsartan) Metabolite M-II [ Time Frame: Pre-dose and at multiple time points (up to 24 hours) post-dose ]
    T1/2 is the terminal elimination half-life (time required for half of the drug to be eliminated from the plasma), calculated as T1/2=ln(2)/λz.

  16. Cumulative Urinary Excretion Ratio of TAK-536 (Azilsartan) [ Time Frame: Day 1 from 0 to 24 hours post-dose ]
    The cumulative urinary excretion ratio (% of dose [TAK-536-equivalent]) of TAK-536 will be calculated from the urinary concentration and volume of each participant.

  17. Cumulative Urinary Excretion Ratio of TAK-536 (Azilsartan) Metabolite M-I [ Time Frame: Day 1 from 0 to 24 hours post-dose ]
    The cumulative urinary excretion ratio (% of dose [TAK-536-equivalent]) of TAK-536 metabolite M-I will be calculated from the urinary concentration and volume of each participant.

  18. Cumulative Urinary Excretion Ratio of TAK-536 (Azilsartan) Metabolite M-II [ Time Frame: Day 1 from 0 to 24 hours post-dose ]
    The cumulative urinary excretion ratio (% of dose [TAK-536-equivalent]) of TAK-536 metabolite M-II will be calculated from the urinary concentration and volume of each participant.

  19. Number of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs [ Time Frame: Up to 15 Days ]
    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. Treatment emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly; or a medically important event.

  20. Percentage of Participants With Remarkable Findings of Clinical Concern From Baseline in Vital Signs [ Time Frame: Baseline and Day 2 ]
    Vital signs are defined as sitting blood pressure, sitting pulse rate and temperature.

  21. Percentage of Participants With Remarkable Findings of Clinical Concern From Baseline in Body Weight [ Time Frame: Baseline and Day 2 ]
  22. Percentage of Participants With Remarkable Findings of Clinical Concern From Baseline in Resting 12-Lead Electrocardiogram (ECG) [ Time Frame: Baseline and Day 2 ]
    A resting 12-lead ECG was recorded. The investigator or subinvestigator (or a qualified physician at the study site) interpreted the ECG results.

  23. Percentage of Participants With Remarkable Findings of Clinical Concern From Baseline in Laboratory Test Results [ Time Frame: Baseline and Day 2 ]
    Laboratory test results are defined as serum chemistry, hematology and urinalysis.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Years to 15 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. In the opinion of the investigator or subinvestigator, the participant's parent or legal guardian is capable of understanding and complying with the study requirements.
  2. The participant's parent or legal guardian is capable of signing and dating a written informed consent form on behalf of the participant prior to the initiation of any study procedures. Written informed assent is also obtained from the participant as much as possible.
  3. The participant is diagnosed as hypertensive (if the participant is not receiving antihypertensive therapy, the diagnosis will be based on the Age- and Gender-Based Blood Pressure Reference for Children. Sitting diastolic blood pressure [DBP] or systolic blood pressure [SBP] is to be in at least the 95th percentile if essential hypertension is present without concurrent hypertensive organ damage and at least the 90th percentile if secondary hypertension is present with concurrent chronic renal disease, diabetes mellitus, heart failure, or hypertensive organ damage).
  4. The participant is male or female and aged 6 to less than 16 years at the time of consent.
  5. The participant weighs at least 20 kg during the observation period.
  6. The participant is capable of taking the tablets provided as study drug.
  7. Participants after renal transplants should meet the following conditions:

    At least 6 months has elapsed from the transplant to the start of the observation period with stable graft function for more than 6 months (and estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m^2) and historical documentation (Doppler echo or computed tomography [CT], magnetic resonance imaging [MRI], etc.) which verify that arterial stenosis is not present in the transplanted kidney. For participants receiving immunosuppressive therapy, the dose should have been stable at least 30 days before study drug administration.

  8. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent to within 1 month after the completion of the study and have a negative pregnancy test result during the observation period.

Exclusion Criteria:

  1. The participant received an investigational drug within 30 days prior to the start of the observation period or is currently participating in another clinical study or post-marketing study.

    Note: This does not apply to participants participating in observational studies without interventional or invasive therapy.

  2. The participant is determined to have poorly controlled hypertension (as a general guideline, when clinical sitting blood pressure is measured, SBP is to be at least 15 mmHg higher and/or DBP is to be at least 10 mmHg higher than the 99th percentile in the Age- and Gender-Based Blood Pressure Reference for Children).
  3. The participant is diagnosed with malignant hypertension or rapidly progressive hypertension.
  4. The participant has severe renal dysfunction (eGFR <30 mL/min/1.73 m^2), dialysis treatment, renovascular disease affecting both kidneys or a solitary kidney, severe nephrotic syndrome not in remission, or serum albumin <2.5 g/dL.
  5. The participant has a history or clinical manifestations of serious cardiovascular, hepatobiliary, gastrointestinal, endocrine (e.g., hyperthyroidism and Cushing's syndrome), hematologic, immunologic, genitourinary, or psychiatric disease; cancer; and/or any conditions that would interfere with the health status of the participant through study participation or would jeopardize study integrity in the opinion of the investigator or subinvestigator.
  6. The participant has left ventricular outflow tract obstruction affecting hemodynamics due to aortic stenosis, aortic valve disease, or the like or is scheduled to have surgery affecting blood pressure (e.g., repair of arterial anomalies) during the study.
  7. The participant underwent a surgical procedure with major bleeding within 6 months before the start of the observation period.
  8. The participant has past or present clinically significant abnormalities on the 12-lead electrocardiogram and is ineligible for the study in the opinion of the investigator or subinvestigator.
  9. The participant has poorly controlled diabetes mellitus (hemoglobin A1c [HbA1c] >9.0% during the observation period)
  10. The participant has any of either alanine aminotransferase [ALT] or aspartate aminotransferase [AST] at least 2.5 times the upper limit of standard value or total bilirubin at least 1.5 times the upper limit of standard value, severe hepatic dysfunction, active liver disease (regardless of etiology), and jaundice during the observation period.
  11. The participant has hyperkalemia exceeding the upper limit of standard value during the observation period.
  12. The participant has a history of hepatitis B, hepatitis C, or human immunodeficiency virus infection at the start of the observation period.
  13. The participant has a history of hypersensitivity or allergy to angiotensin II receptor blockers (ARBs).
  14. The participant requires treatment with prohibited concomitant drug(s).
  15. Peripheral venous blood collection from the participant is difficult.
  16. The participant had a clinically significant acute disease within 30 days from the day before study drug administration.
  17. If female, the participant is pregnant or lactating, or intending to become pregnant before giving consent, during the study period, or within 1 month after study completion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02451150


Locations
Layout table for location information
Japan
Fuchu, Japan
Oofu, Japan
Setagaya-ku, Japan
Sponsors and Collaborators
Takeda
Investigators
Layout table for investigator information
Study Chair: Medical Director Takeda
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT02451150    
Other Study ID Numbers: TAK-536/CPH-103
U1111-1169-6319 ( Registry Identifier: WHO )
JapicCTI-152898 ( Registry Identifier: JapicCTI )
First Posted: May 21, 2015    Key Record Dates
Results First Posted: April 7, 2016
Last Update Posted: April 7, 2016
Last Verified: March 2016
Keywords provided by Takeda:
Drug therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Vascular Diseases
Cardiovascular Diseases
Azilsartan medoxomil
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action